SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Send us your Comments

Never Miss a Story

Sign up for email alerts

 

More Industry Headlines

MEDICA 2014: robotics in the cardiology field Events highlight new advances

Double-jeopardy: multiple medical conditions investigated A new report looks into holistic approach when addressing cardiovascular issues

Toshiba and Johns Hopkins join forces over big data Leveraging big data to improve outcomes

New MR technique offers new insight into multiple sclerosis May help improve treatment monitoring

Is it time to be anti-antibiotics? The cost of over-prescribed antibiotics goes far beyond funds

MEDICA 2014: new imaging technology improves breast cancer diagnosis Shows structures that mammo can't

Iodine-based contrast for CT safe for most patients Goes against the previous notion

September's New Product Showcase This month's roundup of the latest industry products.

Information portal will reveal cost and quality of health care services HCCI works with insurance companies to create it

Researchers unveil non-invasive prostate screening technique Predicts prostate cancer with 98.1 percent accuracy

No cognitive decline seen in breast cancer patients getting "prophylactic" radiotherapy

by Brendon Nafziger , DOTmed News Associate Editor
Breast cancer patients receiving zaps of "prophylactic" radiation therapy to prevent brain metastases while on a drug regimen were no more likely to have cognitive dysfunction than women opting for the drugs alone, according to a new study.

The small clinical trial found cognitive performance scores between the 13 women randomly assigned to receive radiation therapy and the 17 women who chose just to take trastuzumab (Herceptin) were nearly the same, MedPage Today reports.

Story Continues Below Advertisement

Fully integrated PACS, RIS and Voice Recognition at an affordable price

We fit our RIS/PACS to match your workflow, rather than the other way around! Call us at 866-949-7227 or click here to visit our website & see our Advanced Mammography Workstations & Mammography Tracking System built into RIS



No survival differences between the two groups emerged during the two-year-long, prospective, randomized study, presented at the San Antonio Breast Cancer Symposium on December 10, the paper said.

However, fewer women receiving the radiation went on to get brain metastases: three women receiving cranial radiation eventually developed metastases, versus seven in the no-radiation group. But because of the small size of the study, the difference was not statistically significant, according to the researchers, led by Dr. Peter Canney, an oncologist with Beatson West of Scotland Cancer Centre in Glasgow.

Canney said nearly a third of women diagnosed with HER2-positive metastatic breast cancer will go on to have brain metastases. But he said doctors are often reluctant to prescribe preventative radiation therapy out of concerns it would produce cognitive deficits, and he therefore had trouble recruiting patients for the study.

In the study, the patients randomly assigned to the radiation group got 30 Gy in 10 fractions, and were followed up every three months for nine months. None of the women had statistically significant scores on tests for depression, anxiety or quality of life, MedPage said.

Related:


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2014 DOTmed.com, Inc.
ALL RIGHTS RESERVED